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Antibiotics induce polarization 
of pleural macrophages to M2-
like phenotype in patients with 
tuberculous pleuritis
Sisi Wang1, Jian Zhang1,2, Liyan Sui1, Hao Xu1, Qianling Piao1, Ying Liu1,3, Xinglong Qu1,3,  
Ying Sun3, Lei Song3, Dan Li3, Liping Peng3, Shucheng Hua1,3, Guangan Hu  4 & Jianzhu Chen1,4
Pleural macrophages play critical roles in pathogenesis of tuberculous pleuritis, but very little is known 
about their response to anti-tuberculosis antibiotics treatment. Here, we examined whether and how 
pleural macrophages change in phenotype, transcription and function following antibiotics treatment 
in patients with tuberculous pleuritis. Results show pro-inflammatory cytokines were down-regulated 
significantly post antibiotic treatment in the pleural effusions and pleural macrophages up-regulated 
markers characteristic of M2 macrophages such as CD163 and CD206. Differential expression analysis of 
transcriptomes from four paired samples before and after treatment identified 230 treatment-specific 
responsive genes in pleural macrophages. Functional analysis identified interferon-related pathway to 
be the most responsive genes and further confirmed macrophage polarization to M2-like phenotype. 
We further demonstrate that expression of a significant fraction of responsive genes was modulated 
directly by antibiotics in pleural macrophages in vitro. Our results conclude that pleural macrophages 
polarize from M1-like to M2-like phenotype within a mean of 3.5 days post antibiotics treatment, which 
is dependent on both pleural cytokine environment and direct modulatory effects of antibiotics. The 
treatment-specific genes could be used to study the roles of pleural macrophages in the pathogenesis of 
tuberculous pleuritis and to monitor the response to antibiotics treatment.
Tuberculosis (TB) is caused by infection of Mycobacterium tuberculosis in the lung and is a major public health 
problem in the world because of its prevalence and high mortality1. Around 20% of TB patients develop tuber-
culous pleural effusion (TPE), an accumulation of excess fluid in the pleural cavity, due to tuberculous pleuritis, 
i.e., inflammation of the pleura2–4. Tuberculous pleuritis usually presents as an acute illness with fever, cough and 
pleuritic chest pain, and is diagnosed by elevated levels of adenosine deaminase (ADA) and interferon-gamma 
(IFNγ) in the pleural fluid5,6. Tuberculous pleuritis is caused by delayed type hypersensitivity responses to myco-
bacterial antigens in the pleural space with low bacterial burden7. Although ~70% pleural fluid cells are T cells, 
pleural macrophages are also known to contribute to the pathogenesis of tuberculous pleuritis and the outcome 
of different clinic forms of TB8,9.
Macrophages are the first line of defense against invading microbes and mediate innate immune responses 
through pathogen recognition and activation of inflammatory reactions. Depending on the stimulations and 
microenvironment, macrophages polarize to different functional states, including the classically activated 
M1 and the alternatively activated M210. The M1 phenotype is associated with secretion of large quantities of 
pro-inflammatory cytokines and killing of microbes. The M2 type of macrophages exhibits immunoregulatory, 
phagocytosis, and tissue remodeling and repair functions. In TB patients, alveolar macrophages in the lungs are 
directly infected by M. tuberculosis. Depending on the stage of infection and disease development, macrophages 
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can produce either pro-inflammatory and microbicidal responses or immunosuppressive and tissue repairing 
responses11. For example, in newly onset TB patients and during the early phase of M. tuberculosis infection, mac-
rophages exhibit an M1-like phenotype producing pro-inflammatory cytokines and contributing to the develop-
ment of TPE8.
The frontline treatment of M. tuberculosis infection is a combination of four antibiotics: isoniazid, rifampicin, 
pyrazinamide and ethambutol (HRZE). Antibiotics treatment significantly eliminates the bacterial load and 
inhibits the formation of TPE. Although antibiotics are most widely known for their direct microbicidal activ-
ity12,13, increasing evidence suggests that many antibiotics also modulate activities of immune cells14. For example, 
rifampicin is known to induce the expression of CD1 in human T cells and monocytes and therefore immune 
responses to various infections15,16. Isoniazid eliminates antigen-specific T cells by inducing apoptosis in TB ani-
mal models17, and also regulates both adaptive and innate immune responses during its induction of liver injury18. 
Pyrazinamide modulates the host immune response to infection by reducing pro-inflammatory cytokines IL6 
and TNFα production19, and activates the mouse macrophage by inducing expression of CD80, CD86 and 
MHCII20. Isoniazid and pyrazinamide together robustly activate autophagy through reactive oxygen species in 
mycobacterial-infected murine macrophages21. A pertinent question is whether and how antibiotics treatment in 
TB patients modulates macrophage polarization and function.
Recently, O’Garra and colleagues have started to address this question by transcriptional profiling of periph-
eral blood mononuclear cells (PBMCs) from TB patients before and after antibiotics treatment. They report the 
identification of a whole-blood host-response-specific 393-transcript signature, which reflects mycobacterial 
infection, and a whole-blood treatment-specific 320-transcript signature for monitoring the efficiency of anti-
biotics treatment22,23. Because total PBMCs were used, their studies did not define the contribution of specific 
immune cell types. Furthermore, compared to TPE, although peripheral blood is more accessible but it is far-
ther removed from the primary site of mycobacterial infection. Whether and how antibiotics treatment in TB 
patients affects specific immune cell types, such as macrophages, in the proximal site of infection has not been 
investigated.
In this study we have examined changes in phenotype and function of pleural macrophages in TB patients 
before and after antibiotics treatment by assaying their expression of surface markers, transcription profiles 
and phagocytosis activities. Our results show that pleural macrophages are polarized from M1-like to M2-like 
phenotype as early as 2 days post antibiotics treatment. A signature of 230 genes was identified to reflect the 
treatment-specific response in pleural macrophages. Among these genes, some were modulated by direct anti-
biotics treatment of purified pleural macrophages in vitro. Our study defines responses of pleural macrophages 
to antibiotics treatment in TB patients and raises the possibility of therapeutic efficacy of antibiotics in treating 
tuberculous pleuritis by modulating activities of pleural macrophages.
Results
Pleural macrophages are polarized in response to antibiotics treatment. We enrolled 171 
patients with tuberculous pleuritis for studying the effect of antibiotics on macrophage polarization. After exclud-
ing patients with other lung diseases, HIV co-infection, or contraindications to pleural effusion puncture, 135 
patients remained (Table 1). Pleural fluids were collected from 36 patients before and 2 to 10 days after HRZE 
treatment (paired samples). In the remaining 99 patients, pleural fluids were collected either before or after treat-
ment only (unpaired samples). The frequency and phenotype of various immune cells in the pleural fluids were 
Characteristics Statistics
Male/Female 89/46
Ages (years) 35.6 (17~83)
Pleural fluid
 WBC (6 × 109/L) 4.5 (0.6~23)
 Mononecluear cells (%) 72.3 (39~94)
 CD4+ 58.6 (29.8~82.3)
 CD8+ 19.5 (6.9~34.6)
 B 5.7 (0.3~26.9)
 NK 6.3 (0.4~21.4)
 Macrophages 8.5 (0.2~53.6)
 Multinuclear cells (%) 27.7 (6~61)
 ADA (U/L) 84.9 (37~145)
 LDH (U/L) 782.2 (199~1462)
 Protein (g/L) 52.2 (26~88)
 Rivalta test +
Serum
 ESR (mm/h) 48.7 (8~76)
 CRP (mg/L) 65.7 (19~121.8)
CDU 66.6 (27~123)
Table 1. Clinical characteristics of patients.
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determined by flow cytometry using commonly used lymphocyte and macrophage markers (Figs S1 and 1A). 
Overall, CD3+ T cells were most abundant in the pleural fluids with a CD4+ to CD8+ ratio of ~3 to 1, similar to 
a previous report24. The proportion of macrophages in the pleural fluids varied from patients to patients with an 
average of 8.5% (Table 1). The frequencies of CD4+ or CD8+ T cells, B cells, nature killer cells (NK) and mac-
rophages did not change significantly before and after antibiotics treatment in the paired and unpaired analysis 
(Figure S2). However, expression of M2 markers, including CD163 and CD206, was significantly elevated in 
pleural macrophages in both paired (Fig. 1B) and unpaired (Fig. 1C) samples following antibiotics treatment, 
although expression of M1 markers CD80 and CD86 were also increased slightly. The phagocytic activities of 
pleural macrophages to engulf fluorescent beads were decreased following antibiotics treatment with a P-value 
Figure 1. Comparison of surface marker expression by pleural macrophages before and after antibiotics 
treatment. (A) Flow cytometry analysis of CD80, CD86, CD163 and CD206 expression by CD14+ pleural 
macrophages before (BT) and after (AT) antibiotics treatment from a representative patient. Shaded histograms 
show cells stained with isotype control antibody. The numbers indicate percentages of cells within the gated 
regions. (B–C) Aggregated data from paired samples (B, n = 29) and unpaired samples (C, n = 128) showing 
mean fluorescence intensity (MFI) of CD80, CD86 and CD163 expression and percentages of CD206+ cells. 
P values are shown between BT and AT. (D) Comparison of phagocytosis of five paired pleural macrophage 
samples before and after antibiotics treatment.
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of < 0.056 (Fig. 1D). These data suggest that pleural macrophages are polarized following antibiotics treatment in 
patients with tuberculous pleuritis.
Antibiotics inhibit pro-inflammatory cytokine production. We measured the levels of cytokines 
IFNγ, TNFα, IL4, IL6, IL10, IL1β, TGFβ, GM-CSF, IFNα and IFNβ in the paired pleural fluids by ELISA. The 
levels of IFNγ, TNFα, IL6 and IL10 were significantly decreased following antibiotics treatment while the rest did 
not change significantly (Fig. 2). Intracellular IFNγ, TNFα, IL6 and IL10 were assayed in various cell types after in 
vitro stimulation with PMA plus ionomycin. Consistently, the percentages of CD4+ T cells positive for intracellu-
lar IFNγ, TNFα, IL6 and IL10 decreased and the percentages of CD8+ T cells positive for intracellular IFNγ and 
TNFα also decreased (Figure S3A, S3B). Similarly, the percentages of non-T cells positive for intracellular TNFα 
also decreased. RT-qPCR showed that in pleural macrophages the level of IL6 and IFNγ transcripts was signif-
icantly decreased following antibiotics treatment (Figure S3C). In the paired samples, change in cytokine levels 
in pleural fluids was negative correlated with change of macrophage markers (Figure S4). For example, IFNγ, 
TNFα, IL6 and IL10 level was negatively correlated with the expression of CD80 and CD163, whereas TGFβ and 
GM-CSF level was negatively correlated with CD206. Taken together, antibiotics treatment reduces cytokine lev-
els in the pleural fluid by modulating functionality of not only T cells but also non-T cells such as macrophages.
Pleural macrophages polarize to an M2-like phenotype following antibiotics treatment. To 
better understand the effect of antibiotics on pleural macrophages, we determined the transcription profiles of 
pleural macrophages before and after HRZE treatment by RNA-Seq of four pairs of pleural macrophage samples 
with yielding high quality of total RNA. Based on the overall transcription profiles, principle component anal-
ysis (PCA) grouped samples before treatment together and samples after treatment together (Fig. 3A), suggest-
ing the sufficient samples to capture the treatment response. Differential expression analysis revealed that 156 
genes were up-regulated and 74 genes were down-regulated significantly after antibiotics treatment (Fig. 3B and 
Table S1). The differentially expressed genes were enriched with immune regulation and stress response pathways 
(Fig. 3C and Table S2), including response to chemical stimulus (37 genes, P = 5.91e-6), immune response (25 
genes, P = 8.97e-6), response to stress (42 genes, P = 3.86e-5), and immunity and defense (36 genes, P = 1.2e-6). 
Regardless of the enriched category, up-regulated genes were enriched with vascular development and extracellu-
lar matrix remodeling, while down-regulated genes were enriched with interferon-mediated immunity (Table S2). 
Moreover, most M1 marker genes, such as IL6, IL23A, IDO, CCL8 and CXCL10/11, were down-regulated whereas 
M2 marker genes, such as IL10, IRF4, CD163, IL4R, MRC1/2 and CCL18, were up-regulated (Fig. 3D). These 
results suggest that at the genome level, pleural macrophages are polarized to an M2-like phenotype following 
HRZE treatment.
Twenty-two of the 74 down-regulated genes were also down-regulated in previous transcriptional analysis 
of peripheral blood mononuclear cells (PBMCs) in TB patients post antibiotics treatment22,23, whereas only 4 
of the 156 up-regulated genes were up-regulated in PBMCs. The 22 down-regulated genes were enriched with 
interferon-mediated immunity (7 genes, P = 1.2e-10) and immunity and defense (10 genes, P = 8.0e-6), including 
Figure 2. Comparison of cytokine levels in pleural fluids from patients with tuberculous pleuritis before and 
after antibiotics treatment. The indicated cytokines were assayed by ELISA in pleural fluids of 28 patients. P 
values by paired t-test are indicated.
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Figure 3. Pleural macrophages are polarized to an M2-like phenotype by antibiotics treatment. (A) Principal 
component analysis of transcriptional profiles of pleural macrophages from four patients (red, orange, blue and 
green) before (circle) and after (triangle) antibiotics treatment. (B) Heatmap showing differentially expressed 
genes in four pairs of samples. (C) List of the most significantly enriched pathways of differentially expressed 
genes. (D) Heatmap of M1 and M2 gene expression in pleural macrophages before and after antibiotics 
treatment. (E) Comparison of differentially expressed genes to gene signatures of hMDMs stimulated by 23 
different stimuli (Xue et al. 2014). Shown are number of differentially expressed genes in pleural macrophages 
that are either positively (orange bar) or negatively (blue bar) correlated with the corresponding gene expression 
in hMDMs following indicated stimulation. (F) List of top 10 transcription factors that were identified to 
regulate the differentially expressed genes.
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OAS (2′-5′-oligoadenylate synthetase) and IFIT (Interferon-induced protein with tetratricopeptide repeats) fam-
ily members. We also compared expression profiles in pleural macrophages to the gene expression modules in 
human monocyte-derived macrophage (hMDMs) stimulated by various stimuli25. Most differentially expressed 
genes in pleural macrophages before and after antibiotics treatment were negatively correlated with IFNγ/TNFα 
stimulating modules and positively correlated with P3C or TNF_PGE2_P3C (TPP) simulating modules through 
TLR2 (Fig. 3E). Based on master regulation analysis26 of the signature genes and genome-wide regulatory net-
work by Xu et al.25, 7 of the top 10 identified transcription factors (TFs) were interferon responsive, including 
STAT1, FOXO3 and IRF9 (Fig. 3F). These results suggest that while IFNγ and TNFα exert significant effect on 
pleural macrophage polarization, antibiotics may exert separate effect.
Antibiotics exert direct effect on pleural macrophages. Gene expression changes in pleural mac-
rophages after antibiotics treatment are enriched in GO term of “response to chemical stimulus” and most of these 
up-regulated genes were not captured in the whole-blood treatment-specific signature, raising the possibility that 
antibiotics exert direct effect on macrophage polarization. To test this possibility, we purified pleural macrophages 
from patients before antibiotics treatment but treated these macrophages with antibiotics in vitro. We selected 8 
signature genes (COLEC12, HSPA1B, TREM1, CCL18, OAS3, IFIT3, CXCL16, CXCL10) to monitor the change of 
gene expression by real-time PCR. These genes not only belonged to “response to chemical stimulus” but to other 
functional categories such as “immune response” and “response to stress”. Expression of five genes was altered 
by antibiotics treatment in vitro: The levels of COLEC12, HSPA1B and TREM1 transcripts were up-regulated, 
whereas the two IFNγ-mediated antiviral genes OAS3 and IFIT3 were down-regulated (Fig. 4), consistent with 
the in vivo results. However, CCL18, a typical M2 marker, was down-regulated in vitro but up-regulated in vivo 
following antibiotics treatment, and CXCL16 and CXCL10, typical M1 markers and known IFNγ-responsive 
genes, were not significantly changed in vitro. These results show that anti-TB antibiotics directly modulate dif-
ferentiation status of pleural macrophages.
Discussion
TPE is one of the most common forms of extrapulmonary tuberculosis. Pleural macrophages exhibit an M1-like 
phenotype producing pro-inflammatory cytokines and contribute to the initiation and development of TPE8,27,28. 
No study has investigated the treatment-specific response of pleural macrophages in patients with tubercu-
lous pleuritis. Here we examine the phenotypic and functional changes of pleural macrophages post antibiot-
ics treatment by assaying their expression of surface markers, phagocytic function, secretion of cytokines and 
genome-wide transcriptional profiles. Our results from different analyses show that pleural macrophages are 
rapidly polarized from M1-like to M2-like phenotype after antibiotics treatment in vivo.
Differentiating monocytes or macrophages express higher level of CD14 and HLA-DR than circulating or 
resident monocytes. The higher expression level of CD14 and HLA-DR in pleural macrophages comparing to 
monocytes (Supplementary Figure S5A,D), suggests pleural macrophages are not monocytes. However, pleu-
ral macrophages before treatment have lower FSC/SSC comparing to pleural macrophages post treatment 
(Supplementary Figure S5D), suggesting pleural macrophages before treatment tend to be in intermediate status 
during monocytes to macrophage differentiation. Since the total number or proportion of pleural macrophages 
did not change before and post antibiotic treatment (Supplementary Figure 1G), additionally the expression 
Figure 4. Comparison of gene expression in pleural macrophages with and without antibiotics treatment in 
vitro. Pleural macrophages were isolated from five patients before antibiotics treatment and cultured in vitro for 
36 hours with or without antibiotics. Cells were collected for RNA isolation and real-time PCR to quantify the 
transcript level of the indicted genes. Transcript level of each gene was normalized to GAPDH (ct). The ratio of 
ct with and without antibiotics is shown. Error bar, SEM; *P < 0.05; **P < 0.01.
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levels of CD14+ were slightly elevated post treatment (Supplementary Figure S5B,C) and CD206low pleural mac-
rophages had lower FSC/SSC comparing to CD206hi pleural macrophages (Supplementary Figure S5E), these 
results suggest that CD206 expression changes are most likely due to the differentiation of pleural macrophages 
induced by antibiotics treatment but not the reduction of monocytes with low expression of CD206.
Our transcription analysis of pleural macrophages before and after antibiotics treatment identified a 
treatment-specific signature of 230 genes, which significantly enriched a down-regulated functional pathway 
of “interferon-mediated immunity”, such as the interferon-related antiviral gene families29, IFIT (IFIT1, IFIT2, 
IFIT3, IFIT5 and IFITM1) and OAS (OAS1, OAS2 and OAS3). In previous studies, gene expression analysis of the 
whole blood of TB patients also showed interferon signaling and innate immune response genes were gradually 
down-regulated post antibiotics treatment22,23, consistent with the decreased level of IFNγ in the patient serum30. 
These results indicate interferon-mediated genes are significantly responsive to antibiotics treatment not only in 
the peripheral blood but also in the TPE. Moreover, differential expressed genes are negatively correlated with 
IFNγ and/or TNFα stimulating modules and regulated by interferon responsive TFs, indicating the decrease of 
IFNγ and TNFα in the TPE exerts significant effect on pleural macrophage polarization post antibiotics treat-
ment. However, a significant fraction of treatment-specific genes was modulated by direct antibiotics treatment 
of purified pleural macrophages in vitro, demonstrating antibiotics may exert independent effects on the pleural 
macrophage polarization.
Studies have suggested that single anti-TB antibiotics exerts direct immunomodulatory effect on immune 
cells15–19. Among the treatment-specific 230 signature genes, most of them were not present in the whole-blood 
treatment-specific signature22,23 nor IFNγ and/or TNFα stimulating modules, suggesting anti-TB antibiot-
ics might directly regulate gene expression in pleural macrophages. As shown by in vitro antibiotics treatment 
of purified pleural macrophages, the expression of five out of eight selected genes was significantly changed. 
COLEC12, HSPA1B and TREM1 were up-regulated as in in vivo. COLEC12 is a C-lectin scavenger receptor asso-
ciated with host defense by binding to and removal of microorganisms31,32. HSPA1B encodes a 70 kDa heat shock 
protein and has been reported to activate macrophages and enhance phagocytosis33,34. TREM1 plays a crucial role 
in fine-tuning of inflammatory response by enhancing or inhibiting TLR signals through NFκB and PU.135–37. 
TREM1-related signaling was identified as the most important activated pathway during active TB disease in 
blood transcriptome analysis from multiple data sets38. Two antiviral genes IFIT3 and OAS3, IL10-inducing and 
IFNγ-suppressing gene CCL1839 were down-regulated, while strong IFNγ-inducing genes CXCL10 and CXCL1639 
were not changed. IFIT3 and OAS3 can be induced by interferon signal or Pattern Recognition Receptors (PRRs) 
activation29. Interestingly, comparing to expression profiles of human monocyte-derived macrophages (hMDMs) 
to various stimuli, the most positively correlated stimulus is the TLR2 ligand P3C (Pam3Cys) and combination 
of LPS and Immune Complex (LPS_IC). Anti-TB antibiotics treatment induced the TLR2 and TLR4 expression 
in lymphocytes and CD14+ monocytes in pulmonary tuberculous patients40. These results suggest that anti-TB 
antibiotics might directly modulate the TLR signaling to regulate the gene expression in pleural macrophages. 
The master regulation analysis also identified several non-interferon or TNF responsive TFs that regulate the 
differentially expressed genes, such as MAFA, MTF1 and MEF2D. These non-interferon or TNF responsive TFs 
could play a key role in modulating pleural macrophages response to anti-TB antibiotics. Thus, the efficacy of 
antibiotics in treating tuberculous pleuritis may depend not only on direct killing of mycobacteria but also on 
modulating the function of pleural macrophages. Consistent with this notion, differentiation of pleural mac-
rophages to M2-like phenotype may promote tissue repair.
Current management of TB treatment lacks robust tools to monitor the treatment efficiency in the early stage 
during the long-term antibiotics treatment, especially for the treatment of multidrug-resistant TB patients2–4. We 
show that the pro-inflammatory mediators IFNγ, TNFα and IL6 in TPE were decreased significantly post anti-
biotics treatment as short as 2~3 days. The reduction of these pro-inflammatory cytokines was also observed in 
the serum, but not until 2~4 months post treatment30. Because TPE is more proximal to the site of mycobacterial 
infection, the more rapid change of pleural cytokines as well as pleural macrophage phenotype could be valuable 
prognostic biomarkers to monitor the efficiency of antibiotics treatment in TB patients with tuberculous pleuritis.
Methods
Patients and study design. A total 171 adult patients with tuberculous pleuritis were enrolled in this study. 
Participants were recruited from the Infectious Disease Hospital of Changchun, China. Thirty-six patients with 
serious comorbidities, encapsulated pleural effusion, other lung diseases, HIV co-infection, or contraindications 
to pleural effusion puncture were excluded from this study. All patients received a full 2 months of combination 
antibiotics treatment (HRZE) with standard doses of isoniazid (H, 300 mg/d), rifampicin (R, 450 mg/d), pyrazina-
mide (Z, 1500 mg/d) and ethambutol (E, 750 mg/d) followed by 4-month HR treatment without steroid therapy. 
Patients underwent thoracentesis (diagnostic and therapeutic) before chemotherapy and/or after 2~10 days of 
chemotherapy before pleural effusion disappeared. The study protocol was approved by the Ethics Committee 
of the Infectious Disease Hospital of Changchun and The First Hospital of Jilin University. All experiments were 
performed in accordance with the relevant guidelines and regulations. In addition, written informed consent was 
obtained from each subject.
Sample acquisition. TPE was obtained by thoracocentesis under conscious sedation and local anaesthesia 
using a 14 G Klatskin needle. 50~150 ml of urokinase-anticoagulated TPE was immediately deposited in 50 ml 
tube and centrifuged at 1500 rpm at 4 °C for 10 minutes. The cell-free PE was collected and stored at −80 °C before 
use. Pleural effusion mononuclear cells (PEMCs) were separated immediately on Lymphoprep (Fresenius Kabi 
Norge AS, Norway) density gradients from cell pellet.
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Cell surface and intracellular cytokine staining. After pre-incubation with human Fc-receptor binding 
inhibitor (eBioscience, USA) for 15 minutes on ice, fresh PEMCs were stained with fluorochrome-conjugated 
antibodies of CD14, CD80, CD86, CD163, CD206, CD3, CD4, CD8, CD20 and CD56 (BD Biosciences, USA) 
at 4 °C in the dark for 20 minutes. Cells were washed, centrifuged and resuspended in cold FACS Buffer (PBS 
containing 0.1% BSA and 0.01% sodium azide) plus PI before flow cytometry analysis. For intracellular cytokine 
staining, PEMCs were first plated and stimulated with 50 ng/ml PMA and 1 μM Ionomycin (Sigma-Aldrich) sup-
plement with GolgiStop™ (BD Biosciences) for 4 hours or 18 hours. Cells were stained with Live/Dead® Fixable 
Dead Cell green fluorescent reactive dye (Invitrogen, USA), then fixed and stained with IFNγ, TNFα, IL6, IL10, 
IL4 and IL2 using Cytofix/Cytoperm Kit (BD Biosciences). Flow cytometry was performed using a LSR Fortessa 
cytometer (BD Biosciences) and data were analyzed using Flowjo7.6.1 software.
ELISA. TPE supernatant were harvested and assayed for IFNα, IFNβ, IFNγ, TNFα, IL-1β, IL-4, IL-6, IL-10, 
TGFβ, and GM-CSF production by ELISA according to the manufacturers’ protocol from eBioscience, R&D, 
Abcam, Elabscience and Dakewe Biotech Co.
Pleural macrophage purification, RNA isolation, RNA-sequencing and data analysis. Pleural 
macrophages were purified from freshly isolated PEMCs using human CD14 MicroBeads (Miltenyi Biotec, USA). 
Briefly, cells were passed through a magnetic column as CD14-depleted cells. Labeled cells were collected as puri-
fied macrophages. Macrophages were further purified by seeding in 60-mm dish in complete RPMI 1640 medium 
(Gibco, USA) containing 10% FBS (BI, Israel), 100 U/ml of penicillin and streptomycin. Cells were incubated at 
37 °C for 20 minutes and washed off the unattached cells. The purity of macrophages were assessed by Giemsa 
staining to ensure >90% purity. 0.5~1 × 106 macrophages were collected into 1 ml of TRIzol (Ambion, USA) for 
RNA extraction.
The quality and quantity of total RNA were assessed with a RNA-6000 Nano LabChip on a 2100 Bioanalyzer 
(Agilent Inc., USA). cDNA libraries were prepared with SMARTer Universal Low Input RNA Kit (Clontech, 
USA). The libraries were sequenced by HiSeq. 2000 100 PE (Illumina, USA). Paired sequences were aligned to 
the human genome (version hg19) using Tophat241. Raw counts of each gene for each sample were calculated 
by HTseq42. Differentially expressed genes between paired samples before and after treatment were performed 
using edgeR at P-value < 0.05 with a cutoff of 2-fold change43. Differentially expressed genes were annotated 
using online functional enrichment analysis tool DAVID44. RNA-seq data are available in GEO database under 
accession code GSE85037.
To compare to the spectrum of human macrophage activation25, signature genes of each stimulus were 
matched to our 230 treatment-specific signature genes based on their expression change trends. Master reg-
ulation analysis was performed as previously described26. The spectrum data25 was used to construct an 
information-based regulatory network and applied to search for the key transcription factors that regulate the 
230 treatment-specific signature genes.
In vitro anti-TB drug treatment. A combined dose of HRZE for in vitro treatment was used to mimic the 
in vivo treatment based on the maximum human blood plasma concentrations (Cmax) of approximately 12.4 µg/
ml H, 4.0 µg/ml R, 58 µg/ml Z and 4.3 µg/ml E during chemotherapy respectively45. Pleural macrophages were 
purified from PEMCs as described above and incubated with or without HRZE in a 6-well plate at a concentration 
of 1 × 106 cells/well for 36 hours.
Real time RT-PCR. Pleural macrophages from in vitro treatment were collected to isolate total RNA 
using TRIzol. cDNA was reverse-transcribed using Maxima FirstStrand cDNA Synthesis Kit (Thermo, 
USA) according to the manufacturer’s instructions. RT-qPCR was performed in ABI Plus one (Applied 
Biosystems, USA) using FastStart Universal SYBR Green Master (Roche, Germany). Either the 18S ribo-
somal RNA (forward: GCGGCTTTGGTGACTCTA, reverse: CTGCCTTCCTTGGATGTG) or GAPDH 
(forward: CGGATTTGGTCGTATTGGG, reverse: CGGATTTGGTCGTATTGGG) was used as an inter-
nal control for normalization. The gene-specific primer sets were purchased from Qiagen as following: 
COLEC12 (Cat. QT00080192), HSPA1B (Cat. QT01668212), CCL18 (Cat. QT00024066), CXCL10 (Cat. 
QT01003065), IFIT3 (Cat. QT00100030) and OAS3 (Cat. QT01005277) or synthesized as CXCL16 (forward 
and reverse primers: AAACCACCATTCACACTGCG and AGCCACAGTTTACCCTCACAA), TREM1  
(AAGCTCCACCCAAGTCAACTG, and CATCCTCTCAGCACACAGACT), IL1β (CAGAAGTAC 
CTGAGCTCGCC, and AGATTCGTAGCTGGATGCCG), IL6 (GAACTCCTTCTCCACAAGCG and GAAGAG 
GTGAGTGGCTGTCTG), IL10 (GGGAGAACCTGAAGACCCTCA and TGCTCTTGTTTTCACAGGGAAG), 
IFNγ (CATCCAAGTGATGGCTGAACTG and TCGAAACAGCATCTGACTCCTTT), TNFα (ATCCTGG 
GGGACCCAATGTA, and AAAAGAAGGCACAGAGGCCA), TGFβ (CTGTATTTAAGGACACCCGTGC, and 
ATGACACAGAGATCCGCAGTC), GM-CSF (CAGCCCTGGGAGCATGTG and CATCTCAGCAGCAGTG 
TCTCTAC).
Statistical method. in the method as following “Data for flow cytometry and qPCR were presented as 
mean ± SEM. Statistical analysis was performed with Prism5 (GraphPad Software, San Diego, CA). Statistical 
significance between before and after treatment groups was defined as P < 0.05, and obtained with a paired or 
unpaired two-tailed t-test for paired and unpaired samples, respectively. Differences are noted as *P < 0.05, 
**P < 0.01.
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